重症薬疹の発症に関連する因子の解析研究   




研究協力のお願い
協力いただく際の手順
診断基準
研究倫理申請について
同意説明文書について
研究計画
本研究の成果
研究体制 Q&A
関連する研究論文 リンク先 重症薬疹トップページ
 

重症薬疹発症と相関するHLA型及び遺伝子多型に関する研究論文


アロプリノール:高尿酸血症薬

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Hung SI et al., Proc. Natl. Acad. Sci. USA, 102, 4134-4139 (2005)


Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity?. Dainichi T et al., Dermatology, 215: 86-88 (2007)

カルバマゼピン: 抗てんかん薬

TNFa promoter region gene polymorphisms in carbamazepine-hypersensitive patients.   Pirmohamed M et al., Neurology, 56, 890-896 (2001)

A marker for Stevens-Johnson syndrome. Chung WH et al., Nature, 428, 486 (2004)

A marker for Stevens-Johonson syndrome…: ethnicity matters. Lonjou C et al., Pharmacogenomics J. in press (2006)

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Hung SI et al., Pharmacogenet. Genomics, 16, 297-306 (2006)

Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Alfirevic A et al., Pharmacogenet. Genomics, 16, 287-296 (2006)



フェニトイン: 抗てんかん薬

Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced ccutaneous adverse drug reactions. Lee AY et al., Eur. J. Clin. Pharmacol. 60, 155-159 (2004)


アバカビル:抗HIV薬。約5%のヒトに発疹、発熱、等の過敏症状が現れる。この過敏症は黒人で少ない、家族歴があると発症しやすい等、遺伝因子の関与が示唆されている。

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Mallal S et al., Lancet. 359, 727-732 (2002).

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Hetherington S et al., Lancet 359, 1121-1122 (2002)

Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Martin AM et al., Proc. Natl. Acad. Sci. USA 101, 4180-4185 (2004)



ネビラピン抗HIV薬。約5-11%のヒトに発疹等の過敏症症状が出る。

Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. Martin AM et al., AIDS 19, 97-99 (2005)


  • Last Update:2007/6/29

    CopyRight(C)  国立衛研 医薬安全科学部